Latest Regulatory Milestones News

Arizona Lithium advances its Prairie Project with a pioneering commercial development plan for lithium brine extraction, regulatory approvals, and a $1.3 million capital raise to fund initial production.

Alligator Energy Limited has made significant strides in its uranium exploration and development projects, securing critical regulatory approvals and advancing field operations while maintaining a robust cash position. The company’s strategic investments and ongoing drilling programs position it well amid a strengthening uranium market.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

Genesis Resources has completed its acquisition of full ownership of the Plavica JV in North Macedonia and is progressing environmental studies and exploration planning for multiple Australian tenements ahead of 2025 drilling campaigns.

Vanadium Resources Limited has extended its EPC and financing MOU with China Energy and raised A$783,000 via convertible notes, supporting ongoing development of its Steelpoortdrift Vanadium Project amid cost controls and regulatory progress.

PEXA has achieved a crucial regulatory milestone with FCA approval to operate as an Authorised Payment Institution in the UK, paving the way for its Sale & Purchase product launch later this year.

European Lithium Limited reports a maiden 45 million tonne rare earth resource at its Greenland Tanbreez Project, alongside a $24.5 million capital raise by its majority-owned Critical Metals Corp, underpinning its global lithium and rare earth ambitions.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Australian Vanadium Limited reports significant progress across its vertically integrated vanadium strategy, with key project milestones, government approvals, and promising energy storage developments positioning it for growth.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.

Ecofibre Limited reported a $2.2 million operating cash outflow in 3Q25 with total cash at $1.3 million, highlighting mixed progress across its business units and a pressing need to monetise assets to sustain operations.